Please login to the form below

Not currently logged in

BioFocus extends collaboration with Chiesi

BioFocus has announced that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company

BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, has announced that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached €2.5m.

BioFocus and Chiesi began their collaboration in December 2009 and recently extended it for one year. Under the terms of the extended collaboration agreement, BioFocus will provide medicinal chemistry and biology services, with an additional option for ADME (absorption, distribution, metabolism and excretion) services, for an undisclosed Chiesi therapeutic programme. With 250 employees based in the UK, US and Switzerland, BioFocus is a service of Galapagos, the Belgian drug discovery company.

"BioFocus has a high return business rate with clients, and we are pleased that Chiesi has chosen to extend this successful collaboration," said Onno van de Stolpe, CEO of Galapagos. "The quality of the science at BioFocus enables it to sustain its position as a premier provider in drug discovery services."

"The medicinal chemistry and biology work performed by BioFocus has so far helped us to accelerate progress on our therapeutic programmes. We look forward to working with BioFocus to move these programmes forward toward the clinic," said Dr Paolo Chiesi, R&D director and vice-president of Chiesi Farmaceutici. 

18th October 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...